Document is current
Any future updates will be listed below
-
Authors
Camporesi, Elena https://orcid.org/0000-0003-1044-0192
Lashley, Tammaryn
Gobom, Johan
Lantero-Rodriguez, Juan
Hansson, Oskar
Zetterberg, Henrik
Blennow, Kaj
Becker, Bruno
-
Funding
Funding for this research was provided by:
Vetenskapsrådet (2018-02532)
H2020 European Research Council (681712)
Alzheimer's Drug Discovery Foundation (Alzheimer Drug Discovery FoundationAlzheimer Drug Discovery Foundation)
Alzheimerfonden
Åhléns Stiftelse
Swedish State Support for Clinical Research (ALFGBG-720931)
Demensförbundet
Gun och Bertil Stohnes Stiftelse
University of Gothenburg
- License Information
-
More Information
Article History
Received: 2 November 2020
Accepted: 9 January 2021
First Online: 1 February 2021
Competing interests
: HZ has served at scientific advisory boards for Denali, Roche Diagnostics, Wave, Samumed and CogRx, has given lectures in symposia sponsored by Fujirebio, Alzecure and Biogen. HZ and KB are co-founders of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. KB has served as a consultant or at advisory board for Axon, Biogen, CogRx, Lilly, MegQu, Novartis and Roche Diagnostics. OH has acquired research support (for the institution) from Roche, Pfizer, GE Healthcare, Biogen, Eli Lilly and AVID Radiopharmaceuticals. In the past 2 years, he has received consultancy/speaker fees (paid to the institution) from Biogen and Roche.
